计算机辅助发现来自阿育吠陀药用植物的阿尔茨海默氏症的双重目标化合物
Mohibullah Shah1,2, Sadia Pervaiz1, Iqra Ahmad1
1Department of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan.
PloS one
|June 25, 2025
概括
研究人员选了820种阿育吠陀植物化合物来预防阿尔茨海默氏症.
科学领域:
- 药理学和计算化学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是认知能力下降,与粉样β斑块和神经纤维状结有关.
- 像乙胆化酶 (AChE) 和β-分泌酶 (BACE1) 这样的关键酶是阿尔茨海默病的关键治疗点,因为它们参与了疾病的进展.
研究的目的:
- 通过选来自阿育吠陀植物的820种二次代谢物库来发现阿尔茨海默病的新疗法.
- 确定抑制乙胆酶 (AChE) 和β-分泌酶 (BACE1) 活性的化合物.
主要方法:
- 对820种植物性二次代谢物进行虚拟查,以检测它们的AChE和BACE1.
- 分子动力学 (MD) 模拟,包括RMSF,RMSD,键和相互作用能量计算.
- 主要组件分析 (PCA) 和吉布斯自由能源景观分析.
主要成果:
- 确定了15种潜在的配体,主要是来自Centella asiatica的ursane型或dammarene型三二烯.
- 三种化合物, (S) - 埃里奥迪克提7-O-(6-β-O-trans-p-coumaroyl) -β-d-glucopyranoside, sitoindoside-X和1,5-di-o-caffeoyl酸,显示出显著的疗效.
- 这些化合物表现出有利的类似药物的特性,结构化学和ADMET配置文件,支持它们对阿尔茨海默氏症药物开发的潜力.
结论:
- 亚洲菌中含有具有阿尔茨海默病药物发现显著潜力的化合物.
- 鉴定到的化合物显示出对阿尔茨海默病有前途的治疗潜力,需要进一步的实验验证.
- 建议进行进一步的体外和体内研究,以确认这些化合物作为阿尔茨海默病治疗药物的疗效和安全性.
相关概念视频
01:26Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:26Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
01:28Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
214
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
214